Immunologic Staging of Prostatic Carcinoma: Three Years of Experience

Drucker, Jacob; Moncure, Charles W.; Johnson, Charles L.; Smith, Michael Sharwood; Koontz, Warren W.

doi:10.1016/s0022-5347(17)57394-2

Cited by 16 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a small fraction is immunologically cross-reactive, and it is possible that the reported tumor originated from a pancreatic cell clone which secreted this cross-reactive AP. Drucker and Moncure (1978) reported cross-reactivity of bone marrow AP in a 57-year-old woman with chronic granulocytic leukemia. Pontes et a1 (1 978) described a patient with lung carcinoma who had cross-reactive bone marrow AP.…”

Section: Discussionmentioning

confidence: 98%

“…Thus bone marrow RGID may be a more useful indicator of prostatic carcinoma metastatic to bone than conventional techniques. Moncure (1978) has reported the identification of PAP in tissue samples other than bone marrow. The present study confirms its clinical relevance in the management of all four cases reported.…”

Section: Discussionmentioning

confidence: 99%

“…Serial absorption of the antisera with homogenates of several extraprostatic human tissues removed all precipitin bands except those associated with the prostate; two of these stained for PAP. Using comparative radial gel immunodiffusion (RGID) pioneered by Moncure et a1 (1972) a marrow/serum PAP ratio > 1 has been correlated with the presence of bony metastases from prostatic adenocarcinoma (Drucker et al, 1978). We used RGID to assess the presence of PAP in atypical bony and visceral lesions in patients with known prostatic adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunological detection of metastases from prostatic adenocarcinoma

Heaney

Lin

Daly

et al. 1981

Journal of Surgical Oncology

View full text Add to dashboard Cite

In six patients with known prostatic adenocarcinoma, extraprostatic (metastatic) tumor was suspected on radiographic or radionucleotide studies. When cytological examination of tissue obtained by needle aspiration or biopsy was nondiagnostic, radial gel immunodiffusion was used to identify the presence of prostatic acid phosphatase in the tissue. Four specimens demonstrated prostate-specific acid phosphatase activity, permitting the diagnosis of metastatic prostatic adenocarcinoma. The technique is simple and highly specific.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunological detection of metastases from prostatic adenocarcinoma

Heaney

Lin

Daly

et al. 1981

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera

Shevchuk

Romas

et al. 1983

Cancer

View full text Add to dashboard Cite

A series of 39 prostatic carcinomas was characterized in terms of grade, stage, histologic pattern, and serum acid phosphatase values. These cases were studied immunohistochemically with two different heteroantisera, a goat and rabbit antiserum, and with a monoclonal antibody to prostatic acid phosphatase (PAP). Eighty‐three percent of carcinomas had some degree of PAP positivity when stained by the goat anti‐PAP. Seventy percent were positive with the rabbit antiserum, and 59% showed positivity with the monoclonal antibody. Microacinar patterns were consistently the most positive for PAP, followed by cribriform patterns. The least positivity was observed in the undifferentiated, singlefile and sheet‐like patterns. Likewise, there was more PAP positivity in the lower Gleason and Mostofi grades. When the serum PAP positivity (done by counterimmunoelectrophoresis [CIEP]) was compared with tissue positivity (using the same goat antiserum), 37% were positive in both serum and tissue; 48% were negative in serum, but positive in tissue; and in only 9% the tissue sample was negative when the serum was positive. Based on these data, conclusions are drawn about the significance of the serum acid phosphatase elevations and the role of monoclonal antibodies and heteroantisera in clinical–diagnostic and research work.

show abstract

Counterimmunoelectrophoretic studies of serum prostatic acid phosphatase

Romas

Hsu

et al. 1980

The Prostate

View full text Add to dashboard Cite

A counterimmunoelectrophoretic (CIEP) assay for the specific determination of prostatic acid phosphatase (PAP) is described. PAP was obtained from benign human prostatic tissue and a specific antiserum to this enzyme was produced in rabbits and goats. The lowest detectable activity of PAP was at 0.3 IU/l or 4 ng./0.1 ml. This CIEP method was compared to a standard biochemical method (Roy) on a wide spectrum of prostatic and nonprostatic disease. Nonprostatic malignancies and other disorders associated with hyperacidphosphatasemia by the biochemical method were found to be nonreactive for PAP by CIEP. Patients under treatment with various stages of prostatic carcinoma showed comparable elevations by both methods (35%). In untreated patients, the CIEP was statistically most sensitive in stage A (39% by CIEP and 14% by chemical).

show abstract

Immunologic Staging of Prostatic Carcinoma: Three Years of Experience

Cited by 16 publications

References 5 publications

Immunological detection of metastases from prostatic adenocarcinoma

Immunological detection of metastases from prostatic adenocarcinoma

Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera

Counterimmunoelectrophoretic studies of serum prostatic acid phosphatase

Contact Info

Product

Resources

About